BioXcel Therapeutics
BTAI
85 hedge funds and large institutions have $25.8M invested in BioXcel Therapeutics in 2023 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 21 increasing their positions, 34 reducing their positions, and 21 closing their positions.
31% more call options, than puts
Call options by funds: $1.09M | Put options by funds: $835K
1.61% less ownership
Funds ownership: 3.79% → 2.18% (-1.6%)
3% less funds holding
Funds holding: 88 → 85 (-3)
14% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 21
38% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 34
78% less capital invested
Capital invested by funds: $118M → $25.8M (-$92M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$2.73M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.01M |
| 3 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$1.91M |
| 4 |
Millennium Management
New York
|
+$931K |
| 5 |
Morgan Stanley
New York
|
+$698K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.6M |
| 3 |
State Street
Boston,
Massachusetts
|
-$10.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.37M |
| 5 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
-$5.95M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MIM
101
MetLife Investment Management
Whippany,
New Jersey
| – | -$65.6K | -616 | Closed |
|
|
MLICM
102
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$6.76K | -63 | Closed |
|
|
SWM
103
Spire Wealth Management
Mclean,
Virginia
| – | -$872 | -8 | Closed |
|
|
VCM
104
Versant Capital Management
Phoenix,
Arizona
| – | -$173 | -2 | Closed |
|
|
HFS
105
Hantz Financial Services
Southfield,
Michigan
| – | -$101 | -1 | -25% |
|
|
LC
106
Lindbrook Capital
Calabasas,
California
| – | -$147 | -1 | Closed |
|
107
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$404 | +4 | +80% |
|
BTAI Hedge Fund Activity: Q3 2023 in Review
85 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q3 2023, worth a combined $25.8M — down 78% from $118M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of BTAI and 18 opened new positions — a net loss of 3 holders — while 34 trimmed existing stakes and 21 added.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $2.73M. The largest seller was Adage Capital Partners, cutting an estimated $11.1M.
- 85 institutional investors held BioXcel Therapeutics (BTAI) as of Q3 2023, down from 88 in Q2 2023.
- Funds reported $25.8M of BioXcel Therapeutics stock for Q3 2023, down 78% quarter-over-quarter.
- 18 funds opened new BioXcel Therapeutics positions in Q3 2023 and 21 closed out, a net change of -3 holders.
- The largest BioXcel Therapeutics buyer in Q3 2023 was Two Sigma Investments, an estimated $2.73M added.
- The largest BioXcel Therapeutics seller in Q3 2023 was Adage Capital Partners, an estimated $11.1M sold.
Based on aggregated 13F filings for Q3 2023.